<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the effects of intranasal vascular endothelial growth factor VEGF on neurological function and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in ischemic boundary following <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Sprague-Dawley rats were randomized into sham operation group (n = 9), VEGF group (n = 18), and control group (n = 18) </plain></SENT>
<SENT sid="2" pm="."><plain>The VEGF and control rats were intranasally administered (IN) with VEGF or saline, starting three days after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) and daily </plain></SENT>
<SENT sid="3" pm="."><plain>Neurological scores were obtained at 1, 7, and 14 days after MCAO </plain></SENT>
<SENT sid="4" pm="."><plain>Rats were sacrificed at 14 days, the <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (vWF) immunoreactive, BrdU(+)/vWF(+) cells, and microvessels were evaluated respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Compared to the control rats, intranasal administration of VEGF improved behavioral recovery, and increased the number of vWF(+), BrdU(+)/vWF(+) cells, and <z:chebi fb="0" ids="37926">FITC</z:chebi>-<z:chebi fb="0" ids="52071">dextran</z:chebi> perfused microvessels in ischemic boundary (p &lt; .01) </plain></SENT>
<SENT sid="6" pm="."><plain>Our data suggest that intranasal administration of VEGF may induce <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in ischemic boundary and improve behavioral recovery following <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats, which may provide a powerful strategy for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>